Sustainability Phase: PCV13 Vaccination for Elderly Patients aged ≥65 years on Follow Up with TTSH Integrative Family Physician Clinic
Care Process & Redesign
National Healthcare Group Quality Improvement
National Healthcare Group
31 December 2022
To increase PCV13 vaccination rates in elderly patients aged ≥65 years to 70% over a sustained period. PCV13 vaccination sustainability phase achieved long-term integration into clinic workflows with measurable benefits.
Year Submitted: 2022
Published Date: 31 December 2022
Tags: Care Process ＆ Redesign, Productivity, Cost Saving, Quality Improvement, Lean Methodology
About this Content
Aims
To increase PCV13 vaccination rates in elderly patients aged ≥65 years to 70% over a sustained period.
Background
Vaccination rates for PCV13 were low due to cost concerns and limited public awareness.
Methods
Implemented PDSA cycles including improved vaccination workflows, educational materials, and systematic tracking.
Results
Achieved a vaccination rate increase from 24% to 70% with significant patient satisfaction and acceptance.
Conclusion
PCV13 vaccination sustainability phase achieved long-term integration into clinic workflows with measurable benefits.
Lessons Learnt
Comprehensive strategies such as patient education and consistent workflows improve vaccination uptake.
Additional Information
NHG Quality Day 2022: Merit Award for Sustained Safety Initiative
Keywords
PCV13 Vaccination, Elderly Patients, Preventive Care
Innovators' Details
Innovators' Details
Healthcare Cluster(s) | National Healthcare Group |
Organization(s) Involved | Tan Tock Seng Hospital |
Platform(s) | National Healthcare Group Quality Improvement |
Healthcare Professional Group(s) | Healthcare Administration, Nursing, Medical |
Applicable Specialty or Discipline | Geriatric Medicine, Infectious Diseases |
Project Lead(s) | Wong Teck Yee |
Project Member(s) | Zhang Jin |
Connect with this contributor!
Adj A/Prof Wong Teck Yee - teck_yee_wong@ttsh.com.sg
Project Attachment
C_513_TTSH_Quality_Day_2022_Sustainability_Phase_PCV13_Vaccination.pdf